Jackson Walker successfully represented College Station-based Kalon Biotherapeutics LLC in its recent sale of control to FUJIFILM Diosynth Biotechnologies USA Inc. by the State of Texas, acting by and through the Office of the Governor, and The Texas A&M University System. The transaction was completed on Dec. 18, 2014.
Founded in 2011 by the Texas A&M University System, Kalon Biotherapeutics is a biopharmaceutical contract manufacturing organization with experience in seasonal and pandemic vaccine manufacturing. Kalon is a key subcontractor to one of the three Centers for Innovation in Advanced Development and Manufacturing awarded by the U.S. Department of Human and Health Services. The State of Texas provided funding for the development and support of this center though the Texas Emerging Technology Fund.
Kalon Biotherapeutics was represented by a Jackson Walker team led by Byron Egan and Mike Laussade and including Nate Smithson, Jim Griffin, Colter Harris, Pete Wahl, Dave Player, and Chris Rosa. The successful transaction demonstrates the strength of Jackson Walker’s Corporate & Securities practice, which has extensive experience representing clients involved in all types of mergers and acquisitions, and a deep understanding of the unique challenges and sophisticated needs of clients in the Biotech, MedTech, and Life Sciences industry.